LFST LifeStance Health Group, Inc.

Nasdaq Services-Health Services DE CIK: 0001845257
AI RATING
SELL
78% Confidence

Investment Thesis

LifeStance exhibits severe capital inefficiency with ROE of just 1% and ROA of 0.7% despite a fortress balance sheet, indicating systemic operational challenges rather than temporary headwinds. Flat revenue and net income growth combined with 3.5% net margins suggest the company is trapped in a low-return state, unable to generate shareholder value despite generating modest positive free cash flow.

Strengths

  • + Strong balance sheet with conservative 0.19x debt-to-equity leverage
  • + Excellent interest coverage of 12.4x demonstrates debt service capacity
  • + Positive free cash flow of $22.3M provides liquidity cushion and runway for operations

Risks

  • ! Complete revenue stagnation (0% YoY) signals market saturation or competitive headwinds
  • ! Abysmal capital returns (1% ROE, 0.7% ROA) indicate systemic operational inefficiency or structural business model issues
  • ! Thin net margin of 3.5% combined with inability to grow suggests limited pricing power and/or uncontrolled cost structure

Key Metrics to Watch

Financial Metrics

Revenue
403.5M
Net Income
14.2M
EPS (Diluted)
$0.00
Free Cash Flow
22.3M
Total Assets
2.1B
Cash
194.8M

Profitability Ratios

Gross Margin N/A
Operating Margin 5.5%
Net Margin 3.5%
ROE 1.0%
ROA 0.7%
FCF Margin 5.5%

Balance Sheet & Liquidity

Current Ratio
1.48x
Quick Ratio
1.48x
Debt/Equity
0.19x
Debt/Assets
31.2%
Interest Coverage
12.43x
Long-term Debt
282.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T11:36:18.905999 | Data as of: 2026-03-31 | Powered by Claude AI